Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study.

The Korean journal of hepatology - 1 Sept 2010

Lau George K K, Leung Nancy

Abstract excerpt

BACKGROUND/AIMS: Clevudine is a pyrimidine analogue with potent activity against hepatitis B virus (HBV) replication in vitro. In a previous pivotal phase III clinical study, 24 weeks treatment with clevudine 30 mg has been shown to profoundly suppress HBV replication and normalize serum alanine aminotransferase level. METHODS: In this study, we compare the efficacy and safety of clevudine (30 mg daily) versus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Drug Administration Schedule

Share to Drug Resistance, Viral

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Lamivudine

Source

Open in PubMed Open full text

Identifiers

PMID: 20924215
DOI: 10.3350/kjhep.2010.16.3.315
PMCID: PMC3304600

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study.PMID 20924215Read ↗

Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression.Semantic proximity Read ↗

A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B.Semantic proximity Read ↗

Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B.Semantic proximity Read ↗

Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B.Semantic proximity Read ↗

Comparison between clevudine and entecavir treatment for antiviral-naïve patients with chronic hepatitis B.Semantic proximity Read ↗

[Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases].Semantic proximity Read ↗

Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study.Semantic proximity Read ↗

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.Semantic proximity Read ↗

Clevudine: a potent inhibitor of hepatitis B virus<i>in vitro</i>and<i>in vivo</i>Semantic proximity Read ↗

Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.